Displaying 1 - 42 of 42 tests
B-Cell Gene Rearrangement

Detection of clonal IgH gene rearragements by PCR of IgH framework regions 1, 2, 3 and joining regions. In addition, Ig Kappa gene rearrangement analysis is performed using specific oligonucleotides recognizing the Vk, intragenic and Jk regions. Testing is approved for specimens from the state of New York.

Molecular
BCL1/Cyclin D1BCL1/Cyclin D1 is a nuclear protein detectable in formalin-fixed, paraffin-embedded (FFPE) sections and is found in the majority of mantle cell lymphomas. Hairy cell leukemia and plasmacytoma may also express BCL1 with a weaker signal. BCL1 is an oncogene acting as a cell cycle regulator possibly by mediating the growth stimulatory effects of hormone receptor signaling. It has been found to play a major role in both breast and prostate tumorigenesis. Nuclear overexpression of BCL1 has been shown to increase the chance of prostate cancer metastasis to bone, and has been associated with poor prognosis. High nuclear expression of BCL1 is usually associated with poor prognosis. Immunohistochemistry (IHC)
BTK Inhibitor Primary Susceptibility Panel

Concurrent analysis of the following by bi-directional sequencing: CARD11 exons 5 and 6, CD79B exon 5 including common Y196 mutations, CXCR4 C-terminus region, and MYD88 exon 5 including the L265P mutation.

Molecular
CD138CD138 (Syndecan-1) positively stains normal tissue including B-cell precursors and plasma cells. Positive staining in tumors includes myeloma, primary effusion lymphoma. CD138 negative staining comprises mature B-cells and lymphomas (even plasmacytoid lymphomas). Many carcinomas also express CD138. Immunohistochemistry (IHC)
CD19CD19 recognizes a 95kD cell surface glycoprotein which is expressed by cells of the B-cell lineage and follicular dendritic cells. CD19 is a co-receptor of CD21and is an important signal transduction molecule which is involved in the regulation of B-lymphocyte development, activation and differentiation. CD19 may provide useful diagnostic information for the study of B-lymphoproliferative disorders. Immunohistochemistry (IHC)
CD20Normal cell expression of CD20 is found on most B-cells (after CD19 and CD10 expression, before CD21/22 expression and surface immunoglobulin expression) and expression is retained on mature B-cells until plasma cell development, as well as ollicular dendritic cells. In diseased cells, there is positive staining on most B-cell lymphomas, come pre-acute B lymphoblastic leukemia/ lymphoblastic lymphoma (B-ALL/LBL); lymphocyte predominant Hodgkin lymphoma, dimly expressed in T-cells (benign and neoplastic), and spindle cell thymomas. Rixtuximab treated patients may lose CD20 positivity in B cell lymphomas. Immunohistochemistry (IHC)
CD38CD38 is a transmembrane protein that is highly expressed on thymocytes. It is also present on activated T-cells and terminally differentiated B-cells (plasma cells). Other reactive cells include NK cells, monocytes, macrophages and dendritic cells. CD38 may be detected on cells from multiple myeloma, acute lymphoblastic leukemia (ALL, B and T) and some acute myeloid leukemia (AML). Immunohistochemistry (IHC)
CD4CD4, a single chain transmembrane glycoprotein, is found on a T-cell subset (helper/inducer). It is also present on a variety of monocyte-derived cells, including Langerhans and other dendritic cells. The CD4 epitope is absent from immature thymocytes and is expressed during T-cell development. Precursor T-lymphoblastic lymphomas are therefore variable in their expression of CD4, but most mature T-cell lymphomas are positive, with the exception of aggressive NK-cell leukemia, extranodal NK-cell lymphoma, gamma delta T-cell lymphomas, and enteropathy-type T-cell lymphoma. Immunohistochemistry (IHC)
CD79aCD79a first appears at the pre B-cell stage and persists until the plasma cell stage where it is found as an intracellular component. CD79a is found in the majority of acute leukemias of precursor B-cell type, B-cell lines, B-cell lymphomas, and in some myelomas. It is not present in myeloid cells or T-cells. Immunohistochemistry (IHC)
Chromosome Analysis

A wide variety of abnormalities can be identified, providing both diagnostic and prognostic information. Acute leukemias, lymphomas and chronic myeloid and lymphoid disorders are examined cytogenetically in order to establish the exact nature of the acquired genetic change. Rearrangements, also known as translocations, inversions, and deletions, can usually be detected under a light microscope. In most leukemias and lymphomas, changes in chromosome number (ploidy) or chromosome structure (rearrangements) are often observed.
 

Cytogenetics
cMETThe cMET tyrosine kinase receptor, normally expressed by epithelial cells, is overexpressed and amplified in a variety of human tumors, including non-small cell lung carcinoma (NSCLC). High levels of intratumor cMET expression have been associated with a more aggressive biology and a worse prognosis in NSCLC. Engelman et al. reported that cMET amplification induced resistance to gefitinib in a gefitinib-sensitive lung cancer cell line. Moreover, cMET inhibition with a cMET tyrosine kinase inhibitor (PHA-665,752) restored gefitinib sensitivity. Immunohistochemistry (IHC)
DUSP22-IRF4 Rearrangement

Probes: DUPS22-IRF4 gene region at 6p25.3
Disease(s): Anaplastic Large Cell Lymphoma (ALCL), large B-cell lymphoma
 

FISH
Extended Leukemia/Lymphoma Panel - 31 markers

Available as global and tech-only. Markers are CD2, CD3, CD4, CD5, CD7, CD8, CD10, CD11b, CD11c, CD13, CD14, CD15, CD16, CD19, CD20, CD23, CD33, CD34, CD38, CD41, CD45, CD56, CD64, CD71, CD117, CD138, CD235a, FMC-7, HLA-DR, kappa, and lambda.

Flow Cytometry
FGFR3/IgH t(4;14)Probes: FGFR3/IgH t(4;14)
Disease(s): Multiple myeloma, MGUS
FISH
IgAIgA antibody reacts with immunoglobulin Ig alpha chains. It is useful in identifying leukemias, plasmacytomas and B-cell lineage lymphomas. Immunohistochemistry (IHC)
IgDIgD antibody reacts with immunoglobulin Ig delta chains. This antibody is useful when identifying leukemias, plasmacytomas and B-cell lineage lymphomas (in particular marginal zone lymphoma). Cytoplasmic staining is easily identified on paraffin tissue. IgD staining is also seen in normal mantle zone B-lymphocytes. Immunohistochemistry (IHC)
IgGIgG antibody reacts with immunoglobulin Ig gamma chains. This antibody may be useful in identifying plasma cytomas and B-cell lineage lymphomas, and in conjunction with IgG4 staining to assess for IgG4 associated disease. Immunohistochemistry (IHC)
IgH (14q32)

Probes: IgH (14q32)
Disease(s): Lymphoma, NHL, multiple myeloma, MGUS

FISH
IgH Clonality/MRD by NGS

The IgH Clonality/MRD by NGS assay detects clonal populations of B-lymphocytes in a given patient sample through the analysis of the VDJ segment of the immunoglobulin heavy chain (IgH) gene. *Note - Baseline testing of the original primary sample will need to be performed prior to testing on new samples submitted for monitoring of minimal residual disease.

Molecular
IgH/MAF t(14;16)Probes: IgH/MAF t(14;16)
Disease(s): Multiple myeloma, MGUS
FISH
IgH/MAFB t(14;20)

Probes: IgH/MAFB t(14;20)
This probe combination may be ordered separately or added to any of our mye
Disease(s): Myeloma, MGUSloma FISH panels.

FISH
IgM

IgM antibody reacts with immunoglobulin Ig mu chains. This antibody is useful when identifying leukemias, plasmacytomas and B-cell lineage lymphomas.

Immunohistochemistry (IHC)
KappaEach test contains a set of oligonucleotide probes. The intended target is the kappa light chain immunoglobulin messenger RNA (mRNA) in the cytoplasm of immunoblastic cells, plasma cells and plasmacytoid cells. Assessing the light chain immunoglobulin restriction is important in malignant lymphoma diagnosis. The relationship between monoclonal B-cell proliferation and light chain mRNA restriction aids in the distinction between neoplastic and reactive lymphoid proliferations and the evaluation of multiple myeloma, plasmacytoma, lymphomas with plasmacytoid features, immunoblastic lymphomas and reactive plasma cell proliferations. In Situ Hybridization (ISH)
KappaAntibody to the kappa light chain of immunoglobulin is reportedly useful in the identification of leukemias, plasmacytomas and certain non-Hodgkin lymphomas. Demonstration of monotypism in lymphoid infiltrates is a surrogate for clonality, and therefore malignancy. Immunohistochemistry (IHC)
Ki67

Ki67 is a nuclear protein that is expressed in proliferating cells. Ki67 is preferentially expressed during late G1, S, M, and G2 phases of the cell cycle, while cells in the G0 (quiescent) phase are negative for this protein. Increased proliferative activity is associated with more aggressive tumor and decreased disease-free survival period.
Note: Computer-assisted image analysis for Ki-67 is only validated for breast cancer and neuroendocrine carcinoma.

Immunohistochemistry (IHC)
Lambda

Each test contains a set of oligonucleotide probes. The intended target is the lambda light chain immunoglobulin messenger RNA (mRNA) in the cytoplasm of immunoblastic cells, plasma cells and plasmacytoid cells. Assessing the light chain immunoglobulin restriction is important in malignant lymphoma diagnosis. The relationship between monoclonal B-cell proliferation and light chain mRNA restriction aids in the distinction between neoplastic and reactive lymphoid proliferations and the evaluation of multiple myeloma, plasmacytoma, lymphomas with plasmacytoid features, immunoblastic lymphomas and reactive plasma cell proliferations.

In Situ Hybridization (ISH)
MET FISHProbes: MET (7q31) | Centromere 7
Disease(s): Multiple solid tumor cancers including lung (NSCLC), gastric, esophageal, endometrial
FISH
Multiple Myeloma IgH Complex FISH Panel (New York)

Probes: FGFR3/IgH t(4;14) | CCND1/IgH t(11;14) | IgH/MAF t(14;16) | Probes for each translocation may be ordered separately.                      Disease(s): Plasma cell myeloma, multiple myeloma
Note: Plasma cell enrichment will be performed on bone marrow or blood samples unless our client directs us otherwise. (Peripheral blood is not recommended as a screening specimen unless increased plasma cells are seen on blood smear.) Specimens should be received in our laboratory within 72 hours of collection. If enriched samples are insufficient to complete the whole panel, NeoGenomics will prioritize t(4;14) testing unless directed otherwise by our client.

FISH
Multiple Myeloma-MGUS FISH Panel (New York)

Probes: 1p-, 1q+, iso(1q): CDKN2C (1p32), CKS1B (1q21) | +3, hyperdiploidy (Cen 3) | +5, hyperdiploidy (5p15.2, 5q33-34) | +9, hyperdiploidy (Cen 9) | 13q- (13q14, 13q34) | IgH (14q32) | p53 (17p-)
Probes may be ordered separately except +3 and +9 which are combined.
Disease(s): Plasma cell myeloma, multiple myeloma, MGUS
Note: Plasma cell enrichment will be performed on bone marrow or blood samples unless our client directs us otherwise. (Peripheral blood is not recommended as a screening specimen unless increased plasma cells are seen on blood smear.) Specimens should be received in our laboratory within 72 hours of collection. If enriched samples are insufficient to complete the whole panel, NeoGenomics will prioritize p53 testing unless directed otherwise by our client.

FISH
MUM1The MUM1 antibody is specific for the MUM1/IRF4 protein that is overexpressed in late plasma-cell-directed stages of B-cell differentiation. MUM1 is a powerful tool for understanding the histogenesis of B-cell lymphomas. MUM1 protein is an excellent marker for Hodgkin and Reed-Sternberg cells of classical Hodgkin lymphoma in combination with CD30. Furthermore, MUM1 seems to be a marker of prognostic value since it has been found that the expression of MUM1 is associated with the poor prognosis of patients with diffuse large B-cell lymphoma (DLBCL). Immunohistochemistry (IHC)
MYD88 Mutation Analysis

Bi-directional sequencing of exon 5 of the MYD88 gene which includes detection of the common L265P mutation.

Molecular
NeoARRAY™ SNP/Cytogenetic Profile

The NeoARRAY SNP/Cytogenetic Profile is available for hematological, solid tumor, and pregnancy loss indications. With the best genome-wide coverage available, this test employs an enhanced SNP microarray with over 2.6 million SNP and non-polymorphic markers for detection of copy number variants (deletions, duplications, and amplifications) and loss of heterozygosity or uniparental disomy (LOH or UPD) in any chromosome. Sensitivity and specificity for detection of copy number variants >400 kb is >99%. Testing may not reliably detect abnormalities present in less than 20% of the cells tested. Balanced rearrangements, including translocations and inversions, are not detectable by this method. Clients may request NeoARRAY on POC as the sole test, or they may order POC cytogenetics with reflex to NeoARRAY if the POC culture fails or if cytogenetic results are normal. For reflex orders, if there is no cell attachment or growth after 14 days in culture, a cytogenetics failure report will be issued and NeoARRAY will be performed. If there is limited cell attachment after 14 days in culture, NeoGenomics will contact the client for instructions. When array testing is not performed, a fee will be charged for DNA extraction (which is performed upon specimen receipt).

Molecular
NeoARRAY™ SNP/Cytogenetic Profile

The NeoARRAY SNP/Cytogenetic Profile is available for hematological, solid tumor, and pregnancy loss indications. With the best genome-wide coverage available, this test employs an enhanced SNP microarray with over 2.6 million SNP and non-polymorphic markers for detection of copy number variants (deletions, duplications, and amplifications) and loss of heterozygosity or uniparental disomy (LOH or UPD) in any chromosome. Sensitivity and specificity for detection of copy number variants >400 kb is >99%. Testing may not reliably detect abnormalities present in less than 20% of the cells tested. Balanced rearrangements, including translocations and inversions, are not detectable by this method. Clients may request NeoARRAY on POC as the sole test, or they may order POC cytogenetics with reflex to NeoARRAY if the POC culture fails or if cytogenetic results are normal. For reflex orders, if there is no cell attachment or growth after 14 days in culture, a cytogenetics failure report will be issued and NeoARRAY will be performed. If there is limited cell attachment after 14 days in culture, NeoGenomics will contact the client for instructions. When array testing is not performed, a fee will be charged for DNA extraction (which is performed upon specimen receipt).

Cytogenetics
Plasma Cell Add-On Flow Panel

Available as global and tech-only. This add-on panel is available to clarify findings on samples currently having flow cytometry analysis at NeoGenomics and is not available for stand-alone testing. Markers are CD19, CD20, CD38, CD45, CD56, CD117, CD138, cKappa, and cLambda (9 markers).

Flow Cytometry
Plasma Cell Myeloma FISH Panel (non-New York)

Probes: 1p-, 1q+, iso(1q): CDKN2C (1p32), CKS1B (1q21) | +5, hyperdiploidy (5p15) | +9, hyperdiploidy (9q22) | +15, hyperdiploidy (15q22) | 13q- (13q14, 13q34) | IgH (14q32) | 17p- (TP53 17p13.1, NF1 17q11.2)
Probes may be ordered separately except +5, +9 and +15 which are combined.
Global cases with IgH rearrangement will automatically reflex to the Plasma Cell Myeloma IgH Complex FISH Panel unless client has opted out.
Disease(s): Plasma cell myeloma, multiple myeloma
Note: Plasma cell enrichment will be performed on bone marrow or blood samples unless our client directs us otherwise. (Peripheral blood is not recommended as a screening specimen unless increased plasma cells are seen on blood smear.) Specimens should be received in our laboratory within 72 hours of collection. If enriched samples are insufficient to complete the whole panel, NeoGenomics will prioritize p53 testing unless directed otherwise by our client.
 

FISH
Plasma Cell Myeloma IgH Complex FISH Panel (non-New York)

Probes: FGFR3/IgH t(4;14) | CCND1/IgH t(11;14) | IgH/MAF t(14;16) | IgH/MAFB t(14;20)
Probes for each translocation may be ordered separately. 
This panel is available separately or by reflex after the Plasma Cell Myeloma FISH Panel if it detects IgH rearrangement.
Disease(s): Plasma cell myeloma, multiple myeloma
Note: Plasma cell enrichment will be performed on bone marrow or blood samples unless our client directs us otherwise. (Peripheral blood is not recommended as a screening specimen unless increased plasma cells are seen on blood smear.) Specimens should be received in our laboratory within 72 hours of collection. If enriched samples are insufficient to complete the whole panel, NeoGenomics will prioritize t(4;14) testing unless directed otherwise by our client.

FISH
Plasma Cell Myeloma Prognostic FISH Panel (New York)

Probes: 1p-, 1q+, iso(1q): CDKN2C (1p32), CKS1B (1q21) | FGFR3/IgH t(4;14) | CCND1/IgH t(11;14) | 13q- (13q14, 13q34) | IgH/MAF t(14;16) | 17p- (TP53 17p13.1, Cen 17) | Probes for each rearrangement may also be ordered separately.
Disease(s): Plasma cell myeloma, multiple myeloma
Note: Plasma cell enrichment will be performed on bone marrow or blood samples unless our client directs us otherwise. (Peripheral blood is not recommended as a screening specimen unless increased plasma cells are seen on blood smear.) Specimens should be received in our laboratory within 72 hours of collection. If enriched samples are insufficient to complete the whole panel, NeoGenomics will prioritize t(4;14) and TP53 testing unless directed otherwise by our client.

FISH
SMASmooth muscle actin antibody binds to smooth muscle cells and myoepithelial cells. It stains the muscularis propria and muscularis mucosae of the gastrointestinal tract, the uterine myometrium, medial layer of blood vessels, myoepithelial cells of salivary glands and other organs. The antibody does not stain skeletal and cardiac muscle, endothelium, connective tissue, epithelium or nerve. The antibody can be used to identify smooth muscle tumors (leiomyomas and leiomyosarcomas). Immunohistochemistry (IHC)
Standard Leukemia/Lymphoma Panel - 24 markers

Available as global and tech-only. Markers are CD2, CD3, CD4, CD5, CD7, CD8, CD10, CD11c, CD13, CD14, CD16, CD19, CD20, CD23, CD33, CD34, CD38, CD45, CD56, CD64, CD117, HLA-DR, kappa, and lambda.

Flow Cytometry
TP53 Mutation Analysis

Bi-directional sequencing of TP53 exons 4-9.

Molecular
Universal Fusion/Expression Profile

The Universal Fusion/Expression Profile is a targeted RNA sequencing panel that utilizes next-generation sequencing (NGS) to detect all relevant fusion transcripts in 1,385 genes associated with hematologic or solid tumor cancers. It is especially useful for testing patients with rare diseases. Learn more about the Universal Fusion/Expression Profile. See the full 1,385 gene list here.

Molecular
Wright GiemsaCytochemical stain. The Wright Giemsa stain is used to stain peripheral blood and bone marrow smears for study of blood cell morphology. Immunohistochemistry (IHC)